Biovac deal a long term solution

Pfizer and Bio-NTech have reached an agreement with the Biovac Institute in Cape Town to produce COVID-19 vaccines in South Africa. Biovac says it will submit the vaccine to the regulator next year and expects mass production by 2023. It's CEO Morena Makhoana gives us the details. Courtesy #DStv403